•  
  •  
  •  
  •  

2026-07-20 04:25:10

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million

Keywords Selected:  Capsules

Stock Report

  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Fingolimod Capsules, 0.5 mg
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg
  • Natural Biogenex and Fermbox Bio Enter Strategic Framework and Manufacturing Agreements to Strengthen Fermentation-Based CDMO Capabilities
  • Eugia Pharma announces launch of Pomalidomide Capsules in the US
  • NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst&®) in the U.S. market
  • Department of Drug Controller directs Natural Capsules Ltd to close operations of plant
  • Shelter Pharma Limited Launches D3 Cure Capsules
  • ZIM Laboratories Ltd receives approval from CDSCO - Directorate General of Health Services for Naproxen + Esomeprazole Capsules
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Lupin receives approval from U.S. FDA for Lenalidomide Capsules
  • Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
  • Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg
  • Aayush Wellness Ltd launches Brain Fuel Capsules
  • Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg
  • Strides strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg
  • ZIM Laboratories Ltd receives Marketing Authorization for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal, Europe
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
  • Alembic Pharmaceuticals announces USFDA Final Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg
  • Zydus receives final approval from USFDA for Enzalutamide Capsules, 40 mg

Latest Post

  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025